Life Sciences, Health and Pharma

The life sciences, health, and pharmaceutical sectors have undergone significant recent developments. The Council of Ministers adopted an action plan to promote the sector in July 2020 and a legislative and institutional framework overhaul has been launched.

Loucif + Co has developed outstanding expertise in advising companies active in the health, pharmaceutical, cosmetic and chemical sectors.

The firm regularly assists pharmaceutical companies in connection with their asset disposals and acquisitions, manufacturing outsourcing, strategic alliances, and reorganisations. 

We also assist foreign companies intending to set up a business in Algeria with the creation of subsidiaries (including obtaining the necessary regulatory authorisations).

The team monitors legislative and regulatory developments in the pharmaceutical, cosmetics, and chemicals sectors and advises clients on the implications of these developments.


  • Assistance in share or asset acquisition transactions
  • Establishment of joint ventures and strategic alliances (the pharmaceutical sector is subject to an obligation of association with Algerian partners up to at least 51% of the share capital)
  • Reorganisations


  • Drafting and negotiation of strategic licensing, joint venture and collaboration agreements, subcontracting agreements, distribution agreements, service agreements, and medical promotion agreements in the health and pharmaceutical sector
  • Analysis of the commercial policy and distribution schemes of companies active in the pharmaceutical sector, and compliance with the applicable rules


  • Identification and assistance in obtaining the necessary authorisations for the manufacture, distribution, import, or promotion of pharmaceutical products or medical devices
  • Identification and assistance in obtaining the necessary authorisations for the operation of pharmaceutical establishments
  • Assistance with registration and licensing of pharmaceuticals and medical devices (including obtaining operator status for registration decisions)
  • Analysis of the regulations concerning the import of raw materials and finished products
  • Analysis of the legal and regulatory requirements for conducting clinical studies (interventional and non-interventional)
  • Liaison with the authorities (Ministry of the Pharmaceutical Industry, Ministry of Health, National Centre of the Trade Register, ANPP, etc)